NAT2*7 Allele Is a Potential Risk Factor for Adult Brain Tumors in Taiwanese Population

Abstract

Arylamine N-acetyltransferase-2 (NAT2) displays extensive genetic polymorphisms that affect the rates of acetylation of drugs and toxic compounds such as amine carcinogens. The association of NAT2 polymorphisms with adult brain tumors has been unclear. To investigate whether the NAT2 genotype is a risk factor of brain tumors, we determined the frequencies of three common polymorphisms in the NAT2 gene, NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7(G857A), in brain tumor patients and in age-and gender-matched control subjects (n = 27 in each group). Genotyping was carried out using PCR-RFLP and subjects were phenotyped as a fast or slow acetylator based on the genotypes. The odds ratio of NAT2*7 allele frequency was significantly higher in patients with brain tumor than in controls (odds ratio, 6.786; 95% confidence interval, 2.06-22.37; P = 0.003); in the mean time, NAT2*4/*7 genotype was significantly more common in the patient group than in controls (odds ratio, 6.19; 95% confidence interval, 1.68-22.79; P = 0.0039). The tumors in the patients with NAT2*7 allele tended to be high-grade astrocytoma or glioblastoma multiforme (P = 0.016). In conclusion, these data suggest that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan

Influence of NAT2 Polymorphisms on Sulfamethoxazole Pharmacokinetics in Renal Transplant Recipients

“…DNA was extracted from a peripheral blood sample by using a QIAamp blood kit (Qiagen, Hilden, Germany) and was stored at Ϫ80°C until analyzed. Genotyping procedures to identify the CYP2C9*3 (A1075C) allele and the NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7 (G857A) alleles were performed by the PCR-restriction fragment length polymorphism method described by Moridani et al and Liu et al (8,11).…”

NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan

“…1. The strategies to detect and assign NAT2 polymorphisms and the representative results have been previously described [13]. Individuals with 1 or 2 wildtype NAT2*4 alleles were defined as fast acetylators and those with any two polymorphic alleles as slow acetylators.…”

“…Individuals with 1 or 2 wildtype NAT2*4 alleles were defined as fast acetylators and those with any two polymorphic alleles as slow acetylators. Detailed PCR reaction conditions are available upon request [13].…”

High frequency of NAT2 slow acetylator alleles in the Malay population of Indonesia: an awareness to the anti-tuberculosis drug induced liver injury and cancer

“…17 Another reported study showed that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan. 18 A slow acetylation profile also increased risk of developing gastric cancer and bladder cancer in Brazil. 4 Reported studies by Moore et al 19 and Figueroa et al 20 revealed the impact of NAT2 SA on bladder cancer risk in a person who was exposed to carcinogenic NAT2 substrates such as aromatic amines from tobacco smoke.…”